NCT04548960: OncoSNIPE

OncoSNIPE - Study of Molecular Profiles Associated With the Development of Resistance in Solid Cancer Patients

Status unknown NA Last updated 9 September 2021

What this trial tests

NA trial testing cancer patients in CANCER in 600 participants. Status unknown.

Timeline

6 January 2018

Primary endpoint
31 December 2021

31 March 2023

Quick facts

Lead sponsor	Oncodesign SA
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	600
Start date	6 January 2018
Primary completion	31 December 2021
Estimated completion	31 March 2023
Sites	11 locations across France

Drugs / interventions tested

• cancer patients

Conditions studied

• CANCER — all drugs for CANCER →

Sponsor

Oncodesign SA

Who can join

18 and older, any sex, with CANCER. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Precision medicine is considered to be one of the major issues in patient care. A lot of research has already proven itself with the implementation of targeted therapies including immunotherapies offering patients improved response and survival rates. But despite these major therapeutic advances, resistance to anti-cancer treatment is a major obstacle in the care of patients. Indeed, to date, many patients die of cancer, 9.6 million deaths worldwide in 2018. Nowadays, improving understanding of the mechanisms of resistance of cancer cells to anti-tumor treatments is therefore a major issue. The great diversity of molecular mechanisms involved in the phenomena of resistance to treatment, whether intrinsic (de novo, or primary) or acquired (secondary), constitutes a real therapeutic challenge. Indeed, a better understanding of the mechanisms of resistance would make it possible to explore new therapeutic strategies making it possible to circumvent these phenomena of escape in different types of cancer. It is in this context that the OncoSNIPE project was developed. The objective of this project is to identify early and / or late markers of resistance to treatment in 3 different pathologies concerned with resistance issues: triple negative breast cancer or Lum B or locally advanced or metastatic non -small-cell lung cancer or pancreatic cancer. In this project, in order to best cover the diversity of mechanisms involved in these resistances, the investigators propose a multidisciplinary approach with clinical, genomic, transcriptomic and immunological dimensions of the pathology through the data collected from 600 patients (200 for each pathology) for 4 years

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients.
   Vachenc S, Gobbo J, Moujarrebe SE, Desmoulins I, et al · · 2022 · cited 1× · PMID 34991520 · DOI 10.1186/s12885-021-09134-3
2. AI-Driven Patient Screening for Clinical Trials in Pancreatic Cancer: The PANCR-AI Pilot Retrospective Comparative Study.
   Claessens A, Simon A, Manchart A, Desmonts L, et al · · 2026 · PMID 41730173 · DOI 10.2196/80268